UNSPSC 51412900: Vasodilator nicotinic acids

Vasodilator drugs made from 2-, 3-, or 4-pyridinecarboxylic acids. pyridine derivatives substituted with a carboxy group at the 2-, 3-, or 4-position.

UNSPSC 51412900 Vasodilator nicotinic acids is a Class code tracking pharmaceutical products, though recent state and local solicitations show the code's practical application spans emergency medical and pharmacy benefit programs far broader than the narrow commodity name suggests. State and local agencies procuring under this code are acquiring advanced life support medications, generic multi-source pharmaceuticals, and over-the-counter products for emergency services, state employee health plans, and cooperative purchasing networks. Issuing bodies include municipal fire departments (Tampa Fire Rescue through the City of Tampa Purchasing Department), state health and human services commissions (Texas HHS Commission), and regional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance or MMCAP, which serves state and local government facilities across multiple states including Oregon). The work solicited ranges from small, time-sensitive sealed-bid procurements for specific life-support medications to large, multi-year framework agreements for pharmaceutical supply chain management across state and local networks.

Recent opportunities show activity in Florida, Texas, and Minnesota. The City of Tampa Purchasing Department issued an IFB (Bid No. 26-P-00188) on April 24, 2026, for Advanced Life Support Medications including Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials for Tampa Fire Rescue, with a bid deadline of April 8, 2026, and an estimated contract value of $40,000.00; this procurement includes a Small Local Business Enterprise sheltered-market 5 percent bid discount and one-year initial term with options for two additional one-year renewals. The Minnesota Department of Administration's Office of State Procurement, on behalf of MMCAP, posted an RFP (S1070000015802) on January 20, 2026, due March 26, 2026, to establish multiple framework contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (Cencora, Cardinal Health 110/112, and Morris & Dickson), effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling exploratory procurement intent before formal RFP issuance.